A recent study published in the Archives of Internal Medicine concluded that, while "alternative and complementary therapies are generally ineffective for treating menopause-related symptoms," Remifemin, a herbal prepration of the black cohosh root, elicited clear symptomatic relief.
The July 24 review article was welcomed by USA-based Enzymatic Therapy, a provider of therapeutic-dosage natural medicines and nutritional supplements. Remifemin is its proprietary, standardized extract (uniform dosage) of pure black cohosh root called RemiSure, which it claims is the most obstetrician/gynecologist-recommended non-prescription brand of menopause treatment.
The clinical reviewers wrote that "a single large trial showed a benefit for vasomotor symptoms with the black cohosh Remifemin," which is "consistent with older German studies," adding that results from two studies "were confounded by concurrent use of tamoxifen, known to exacerbate hot flashes," while another used a "more unusual (research) preparation, BN01055."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze